Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KYV-101 in refractory dermatomyositis
NCT06298019Phase 1Recruiting
- Sponsor
- Stanford University
- Start
- Aug 2024
- Primary completion
- Apr 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mivocabtagene autoleucel in dermatomyositis (DM), sponsored by Stanford University. Primary endpoint: Number of participants experiencing adverse events at 24 weeks. Started Aug 2024; status: recruiting.
02
Drugs
mivocabtagene autoleucel
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT06298019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06298019.